16% global market share and 80 commercial projects: WuXi AppTec (02359) persists in doing the right things. The small molecule pipeline has reached 167 projects in the third phase and commercial projects.

On January 14, 2026, WuXi AppTec (603259.SH, 02359) delivered a keynote speech at the 44th J.P. Morgan Healthcare Conference and provided updates on the company's business progress. According to data disclosed by the company, as of the third quarter of 2025, the total number of small molecule CDMO pipelines reached 3,430, accounting for 16% of the global clinical stage new drug pipelines, with 167 of them being in phase three or commercialization projects. The company reviewed the number of phase three and commercialization projects in recent years and the corresponding revenue generated. Since 2022, the number of phase three and commercialization projects has increased from 107 to 167, representing a growth of 56%. Correspondingly, the revenue has increased from 4.7 billion yuan to 10.3 billion yuan in 2024, and is expected to reach a new high this year. Recently, oral medication is accelerating its substitution for injectables in mainstream therapy areas globally, becoming the NEW FOCUS in the pharmaceutical industry due to its significant advantages in dosing convenience. Just recently, industry media Endpoint News listed "Pills" as one of the key words for 2025, reflecting the strong rise of this track - from cholesterol-lowering drugs, psoriasis treatments to new generation weight loss drugs, oral formulations are continuously expanding into areas such as obesity, heart disease, inflammatory diseases, seizing market share that was previously dominated by large molecule biopharmaceuticals.